comparing clinical outcome and bacteriological eradication rates for patients with acute streptococcal tonsillopharyngitis treated with penicillin or other antimicrobial agents. Studies were identified using MEDLINE, and clinical outcome and bacteriological eradication at end of treatment and 2 weeks after end of treatment were ascertained. Any longerterm follow-up was also noted, along with treatment-related adverse events and compliance. Clinical efficacy rates between penicillin and comparator antibiotics were generally high and similar. Bacterial eradication rates were more variable and, 2 weeks after treatment, ranged from 64% to 93% for penicillin and 31% to 98% for comparators. Simpler dosing schedules and shorter therapy durations produced higher compliance rates. This review highlights the similarities and differences between treatment with penicillin and a wide range of comparator antibiotics. Therapy for acute group A streptococcal pharyngitis should combine excellent clinical efficacy, high bacteriological eradication rates, good tolerance and a simple, convenient dosing regimen.
Introduction
Tonsillopharyngitis is a common infection, 1 with general practitioners in Europe consulted at least once a week by patients with sore throats. 2 Those most susceptible are children aged between 5 and 15 years, 3 with peak incidence occurring during the first few years of school, 4 and a second, smaller peak in incidence occurring in children aged 12 -13 years, 5 which is thought to coincide with the move from primary to secondary schooling. Infection is spread by person-toperson contact, most likely via droplets of saliva or nasal secretions. 4 A high proportion of cases of pharyngitis are viral in aetiology, with rhinovirus, influenza virus, coronavirus and adenovirus implicated in infections. Bacterial causes include Streptococcus pyogenes (group A β-haemolytic streptococci; GAS), Staphylococcus aureus, Haemophilus influenzae and anaerobes. 6 Of most concern to physicians are infections due to GAS, which account for approximately 20% of cases and can cause sequelae. 1 GAS infections cannot be reliably distinguished clinically from pharyngitis due to other causes; thus, a definitive diagnosis requires either a rapid streptococcus test or culture of a throat swab sample. 7, 8 In the absence of serious but rare complications and sequelae, most cases of GAS tonsillopharyngitis are self-limiting. Usually fever abates within 3 -5 days, and virtually all acute signs and symptoms subside within 1 week, although several additional weeks may be required for the tonsils and lymph nodes to return to their usual size. 4 
Sequelae of GAS pharyngitis
In patients with confirmed GAS tonsillopharyngitis, antibiotic therapy is indicated to eradicate the infecting pathogen, prevent development of suppurative and nonsuppurative complications, 9 and reduce further transmission of the infection.
Suppurative complications of GAS pharyngitis include other upper respiratory tract infections, abscesses, mastoiditis, meningitis, necrotizing fasciitis and streptococcal toxic shock syndrome. 6, 9 These sequelae may be rare, but nonetheless some of them are serious. The use of antibiotics has been shown to reduce the subsequent development of acute otitis media and acute sinusitis to about 25% and 50%, respectively, of the rates seen with placebo administration. 10 Non-suppurative sequelae reported from GAS infections are acute rheumatic fever and acute glomerulonephritis. 10 Acute rheumatic fever is now a relatively rare complication of GAS tonsillopharyngitis in Westernized countries, with approximately 0.5 cases per 100 000 school-aged children reported annually. This contrasts with the situation in developing countries, where it remains an endemic disease, with incidences ranging from 100 to 200 per 100 000 school-aged children, and is a major cause of cardiovascular mortality. 1 The hypothesis remains that the pathogenesis of acute rheumatic fever requires both primary infection of the throat, by so-called rheumatogenic GAS strains, and the presence of still obscure genetic and acquired-host factors. 11 In addition, the incidence of acute rheumatic fever is markedly affected by primary prophylaxis (that is, adequate antibiotic treatment of GAS pharyngitis).
The evidence surrounding the other nonsuppurative complication of GAS tonsillopharyngitis -acute glomerulonephritissuggests a trend for protection by antibiotics. At present, however, there are insufficient cases for a definitive statement. 10 
Requirements of an antibiotic for GAS pharyngitis
A number of antibiotics are licensed for the treatment of GAS tonsillopharyngitis. The aim of these therapies is to achieve clinical cure, but therapy should also eradicate the infecting bacteria. Bacterial eradication leads to both a reduction in bacterial transmission and removal of the bacteria from the infection site, thereby eliminating as much as possible the risk of complications and sequelae. The antibiotic should also be well tolerated and achieve good rates of compliance (usually optimized by short durations of therapy with a minimum number of doses 12 ).
The recent Infectious Diseases Society of America Practice Guidelines 3 recommend antibacterial treatment of acute streptococcal tonsillopharyngitis, to shorten the course of the illness and prevent sequelae.
Therapeutic options
For many years, penicillin has been the mainstay of GAS tonsillopharyngitis therapy. The efficacy of intramuscular benzathine penicillin G for preventing acute rheumatic fever was shown in a study in Costa Rica, when the Costa Rican government recommended intramuscular penicillin for all streptococcal throat infections. This resulted in a dramatic reduction in cases of acute rheumatic fever, from a high of 120 cases per 100 000 of the population in 1950 to only 0.9 cases per 100 000 in 1990. 13 Penicillin G injections are painful, so oral penicillin is a more common therapy but is not ideal and cannot be used for all patients. Some patients display a hypersensitivity reaction to penicillin and should be treated with an agent from a different class of antibiotics. The palatability of the oral suspension of penicillin can also cause compliance problems in children. 9 An additional disadvantage of penicillin is the frequency and duration of dosing; some schedules require dosing up to four times daily for 10 consecutive days. This intensive regimen has been linked to lack of compliance and subsequent treatment failure.
An interesting hypothesis explaining antibiotic treatment failure is copathogenicity, in which bacteria susceptible to one class of drugs are protected by other, co-localized bacterial strains that lack the same susceptibility. 14 In the case of tonsillopharyngitis, β-lactamase-producing oropharyngeal bacteria may degrade penicillin before it can exert its antibacterial effect on GAS. 15, 16 Other possible causes of penicillin treatment failure are eradication of normal protective pharyngeal flora 17 and penicillin tolerance. 14, 18 Penicillin tolerance occurs when streptococcal bacteria are repeatedly or continuously exposed to sublethal antibiotic concentrations and become increasingly resistant to eradication. 14 Group A streptococci are considered extracellular pathogens, but recent studies have demonstrated that strains of this bacterium can internalize within epithelial cells, both in vitro and in vivo. 17 The intracellular niche may protect the bacterium from penicillin, as penicillin does not gain high intracellular concentrations. An antimicrobial agent with activity against intracellular pathogens may be a useful option against this particular form of penicillin failure.
Penicillin V is regarded as the first-choice treatment, but a number of alternatives have been studied for the management of GAS tonsillopharyngitis. Current guidelines recommend second-line therapy with macrolides or first-generation cephalosporins. 3 
Comparative studies of antibiotics used to treat GAS pharyngitis
Fourteen studies comparing the clinical efficacy and bacterial eradication rates of penicillin with other antibiotics licensed for this indication were published between January 1997 and August 2003 (Table 1) . 19 -32 All studies measured clinical and bacteriological success at end of treatment, usually 10 -14 days after study enrolment, but in three studies this was determined after 14 -19 days 23,24 or 20 -24 days 20 . Seven studies reported clinical and bacteriological responses approximately 1 -2 weeks later (generally days 28 -30), 21, 22, 24, 28, 29, 32 and in one other study only bacteriological responses were reported. 23 Types of comparator, dosages, patient ages and treatment-related adverse events (TRAEs; including discontinuation rates) are detailed in Table 1 
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In studies that evaluated patients approximately 2 weeks after the end of therapy, the incidences of clinical and bacteriological success were usually lower, due to cases of relapse or asymptomatic recolonization. Clinical efficacy of penicillin at this time-point was between 82% 28 and 95%, 21 which in most studies was about 2 percentage points below the end-oftherapy results (with the exception of two studies, the first of which showed a reduction of 12 percentage points between the end of therapy and day 28 -30 measurements, 28 and the second of which showed a gain of 5 percentage points; 32 Fig. 3 ). Clinical efficacy rates among the comparator antibiotics ranged between 81% (clarithromycin 28 ) and 96% (cefdinir 24 ). Bacteriological eradication rates at days 28 -30 are presented in Fig. 4 . Negative throat cultures were found in 68% 21 to 93% 23 of patients approximately 2 weeks after completion of penicillin therapy; for the comparator antibiotics, this range was from 31% (azithromycin 10 mg/kg per day 21 ) to 98% (cefdinir 23 ). Most of the patients with a positive GAS throat culture at 2-week follow-up were asymptomatic, indicating recolonization. By ribotyping the GAS isolates, my group has recently shown that, in the majority of cases, bacteriological failure was due to persistence of the same GAS strain, and bacteriological relapse was caused by the same GAS strain, presumably from an endogenous source. 21 
RESULTS AFTER LONGER-TERM FOLLOW-UP
Two studies 21, 25 reassessed patients after 6 -7 months. One found that clinical success rates fell from end-of-therapy levels of cefpodoxime proxetil 92%, amoxycillin/clavulanate 95%, and penicillin 89% to month 6 -7 values of cefpodoxime proxetil 83%, amoxycillin/ clavulanate 69% and penicillin 70%. 25 This
CLINICAL EFFICACY -PRIMARY ENDPOINT
Analysis of these studies shows that clinical efficacy at end of therapy with penicillin remains around 90% or higher in all studies except two. The exceptions are the study by Gopichand et al. 19 (71%), where only half the usual recommended dose of penicillin was used in children weighing less than 27.22 kg ( Table 1 
BACTERIOLOGICAL ERADICATION -PRIMARY ENDPOINT
When eradication of GAS is considered as an endpoint, the results are more variable (Fig. 2) . Bacteriological eradication with penicillin at end of therapy ranged from 55% 19 to 100%, 25 with the majority of results lying between 80% and 90%. It should be noted that the response of only 55% was achieved in the study using a lower dose of penicillin. 19 The eradication rates with amoxycillin were 79% 19 and 76% 20 and the majority of cephalosporin antibiotics produced eradication rates of 90% or higher. 23 -26 Within the macrolide/azalide class of antibiotics, the lowest rate of eradication was achieved with azithromycin 10 mg/kg per day (38% and 58%), 21, 22 followed by josamycin (82%), 32 and clarithromycin-modified release (83%). 29 In contrast, once-daily azithromycin at a total dose of 60 mg/kg over 3 days 22 and clarithromycin 28 achieved bacteriological eradication rates of 94%.
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long-term follow-up established a lower rate of recurrence of acute pharyngitis due to any bacterium in patients treated with cefpodoxime proxetil compared with those treated with either amoxycillin/clavulanate or penicillin. In my study, the patients were reassessed at month 1, month 2, month 4 and month 6 after start of initial antibiotic treatment for acute GAS tonsillopharyngitis. 21 Unusually high recolonization rates with GAS were observed in both treatment groups (penicillin V 45% and azithromycin 61%), which did not correlate with possible concomitant viral infections in the patients, GAS carriage in one parent/guardian or any reduced antimicrobial susceptibility. The majority (> 95%) of recolonized patients remained asymptomatic. In addition, prescription of any additional antibiotics for GAS pharyngitis was measured during the 6 months following therapy. The incidence of additional antibiotic use was similar for those originally treated with azithromycin (28%) or penicillin V (30%). Despite the low rate of GAS eradication with azithromycin therapy, there was no increase in the rate of GAS sequelae compared with those in patients treated with penicillin V. GAS-related pathology possibly developed in two azithromycin-treated patients (proteinuria or glomerulonephritis) and six penicillin V-treated patients (proteinuria and/or glomuerulonephritis or reactive arthritis) during the course of the 6-month study. All of these events disappeared spontaneously within 1 -3 weeks and none were considered drug-related.
TREATMENT-RELATED ADVERSE EVENTS AND COMPLIANCE
To try to evaluate other factors that can impact on prescribing decisions, the level of TRAEs (including discontinuation rates; Table 1 ) and compliance were noted for each study, if the information was available.
Comparison of these factors is possibly more difficult across studies as all are measured with a greater degree of subjectivity than clinical and bacteriological efficacy.
In general, very few patients needed to discontinue therapy due to a TRAE. The rate of discontinuation was uniformly low across all treatments and was ≤ 5% for all antibiotics reviewed.
The rate of TRAEs was also generally low in the majority of studies. In two studies, the incidence of all AEs was recorded, rather than of TRAEs. 29, 30 In the remaining studies, reported levels of TRAEs were very variable. Using the incidence in patients treated with penicillin V, levels varied from 1% 26 to 42%. 28 This makes a tolerability comparison across competitor antibiotics difficult.
Compliance data provide a measurable outcome across the studies that recorded this information. In general, antibiotics with simpler dosing schedules (once daily) and shorter durations of therapy produced higher rates of patient compliance. Azithromycin (once daily for 3 days) produced rates of compliance of 94% or 95% compared with only 62% with penicillin V therapy (P = 0.0001). 22 Better compliance was achieved with cefpodoxime proxetil (twice daily for 5 days) compared with amoxycillin/clavulanate or penicillin V (both three times daily for 10 days; P < 0.001 for both comparisons), 25 and for clarithromycin (twice daily for 5 days) versus penicillin V (three times daily for 10 days; P = 0.008). 28 Comparison of compliance in studies with similar dosing schedules revealed very similar levels. With either amoxycillin or penicillin V therapy (both three times daily for 10 days), roughly half of patients completely finished their course of medication and approximately one-third missed one or two doses, with the remaining patients missing three or more doses. 19 In the
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other amoxycillin versus penicillin study, roughly 70% of patients were fully compliant. 20 
Summary
This review confirms the similarity in rates of clinical efficacy between traditionally firstand second-line treatments for GAS tonsillopharyngitis. GAS tonsillopharyngitis, however, has a high spontaneous cure rate: in > 60% of patients receiving placebo their sore throat had resolved within 7 days. 2 Hence, use of clinical cure as a measure of the efficacy of an antibiotic is unlikely to be reliable.
Of more interest is the incidence of eradication of GAS, as this prevents the progression of GAS tonsillopharyngitis to acute rheumatic fever and suppurative complications. In addition, pathogen eradication would also be expected to reduce the rate of spread of the infection. The incidence of GAS eradication approximately 2 weeks after completion of an antibiotic course is a particularly useful measure, as this excludes those with negative throat cultures due to persistent antibiotic concentration in swab material ('carry-over' effect).
Results of the studies published within about the past 5 years indicate that the incidence of GAS eradication with penicillin does not always reach the levels achieved with comparator antibiotics. Kaplan et al. 33 reported that 35% of patients treated with oral penicillin and 37% of patients treated with intramuscular penicillin G were bacteriological failures at either days 10 -14 or days 29 -31 of the study. The absence of eradication of the pathogen in more than one-third of cases is an interesting and potentially worrying finding. Similar findings of bacteriological failure with penicillin have been reported by Brook, 16 in up to 20% of patients; Sela and Barzilai, 17 in up to 35% of tonsillopharyngitis patients; and Curtin-Wirt et al. 20 in up to 36% of children with tonsillopharyngitis. The results from most of the studies reviewed, however, do not suggest such a large disparity between penicillin and comparator antibiotics.
In this review, a low rate of bacterial eradication at end of therapy (38%) was seen with 10 mg/kg per day, 3-day azithromycin therapy. A further study, however, with a total dose of 60 mg/kg, reported a bacteriological eradication rate of 94%. 22 This suggests that the higher dose of azithromycin is more appropriate for GAS pharyngitis. This increase in dose was not associated with any increase in the side-effect profile of azithromycin compared with the once-daily 10 mg/kg per day dose for 3 days. Subjectivity in reporting AEs may have been especially biased in the study by Cohen et al., 22 as under-reporting would be expected with open-label penicillin V compared with the two azithromycin treatments that were administered in a double-blind fashion. An earlier study, comparing azithromycin 10 mg/kg per day for 3 days with 20 mg/kg per day for 3 days and penicillin V, found similar rates of clinical success and bacteriological eradication with the higher dose of azithromycin and penicillin. Similar incidences of AEs were associated with all three antibiotics.
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Conclusion
In conclusion, although clinical efficacy rates remain high with penicillin V and a wide range of comparator antibiotics, GAS eradication rates are variable. Ideal therapy combines excellent clinical efficacy and high bacteriological eradication rates with a good tolerability profile and a simple dosing regimen to maximize patient compliance.
